Zymeworks Holdings Inc. (ZYME) used the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, to update investors on its growing portfolio of oncology programs, commercial traction for its approved lead drug, and a strengthened balance sheet driven by a royalty-backed financing deal.
Shares in the Calgary-based developer of antibody-based therapies closed around $26.24, down 0.76%, with after-hours trading at $26.07. The stock has delivered a 71% return over the past year, and Zymeworks carries a market capitalization of approximately $1.91 billion.
Chief Executive Ken Galbraith emphasized that the company holds more than $300 million in cash, maintains a current ratio of 6.32, and holds more cash than debt — a position bolstered by a $250 million financing facility secured from Royalty Pharma against future zanidatamab cash flows. Half of the proceeds were allocated to the firm's ongoing share-repurchase program, which since the summer of 2024 has bought back 10.5 million common shares, representing roughly 14% of outstanding stock, at a cost of $215 million. The remainder funded Zymeworks' first major acquisition: a deal to acquire parts of Theravance Biopharma, adding the YUPELRI profit-share agreement, steady revenue from marketed products, and additional research assets.
Zanidatamab, or Zani, won FDA approval in first-line HER2-positive gastric and gastroesophageal adenocarcinoma, improving median overall survival by seven months versus trastuzumab, the prior standard of care for more than a decade. Jazz Pharmaceuticals commercializes the bispecific antibody in the U.S., while BeiGene handles the Asia-Pacific territory. Jazz reported that formulary placement and J-code coverage were secured at 90% of relevant treatment centers ahead of approval. The company also plans additional clinical studies in metastatic colorectal cancer, HER2-overexpressing non-small cell lung cancer, early gastric cancer, and early breast cancer.
Commercial guidance remains robust: Jazz Pharmaceuticals has projected peak sales for zanidatamab between $3 billion and $5 billion, while Johnson & Johnson — which co-develops the KLK2/CD3 T-cell engager pasritamig with Zymeworks — guided its peak-sales potential at $1 billion to $5 billion.
Looking ahead, Zymeworks outlined a busy 2026. Phase III data for pasritamig are expected this year, and two further programs — the trispecific T-cell engager ZW209, featuring CD28 costimulation, and the dual-engineered checkpoint inhibitor ZW1528 targeting the IL-4 receptor and IL-33 — are slated to enter the clinic. Three pan-RAS inhibitor antibody-drug conjugate programs were previously disclosed at the AACR 2024 meeting. Zanidatamab's Phase III trial in metastatic breast cancer is expected to fully recruit by mid-next year, with a readout anticipated in late 2027 to early 2028.
Zymeworks forecasts fiscal 2026 revenue growth of 176% and expects earnings of $1.26 per share.
Other assets on deck include ZW191, a folate receptor-alpha ADC with a topoisomerase payload; ZW251, aGPC3-targeted ADC; and ZW220, targeting NaPi2b.
